CoreCap Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

CoreCap Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-108	Closed	-$1.45K	–	2658
2024 Q2	$1.45K	Hold	108	–	–	﹤0.01%	1361
2024 Q1	$1.79K	Buy	+108	New	+$1.66K	﹤0.01%	2145
2022 Q4	$42.7K	Buy	+3,107	New	+$45.5K	﹤0.01%	1039
2022 Q3	–	Sell	-9,107	Closed	-$138K	–	812
2022 Q2	$138K	Buy	+9,107	New	+$140K	0.01%	596
2022 Q1	–	Sell	-5,100	Closed	-$121K	–	827
2021 Q4	$121K	Buy	+5,100	New	+$142K	0.01%	678

Other funds holding CNCR

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SWA

SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CoreCap Advisors's CNCR Position: Q3 2024 in Review

CoreCap Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2024, closing a stake of 108 shares — an estimated $1.45K sold.

CoreCap Advisors first reported a position in CNCR in Q4 2021 and held it in 5 quarters. The position peaked at $138K in Q2 2022. 11 funds tracked by Wall St. Rank hold CNCR as of Q3 2024.

CoreCap Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2024 after selling out during the quarter.
CoreCap Advisors sold 108 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2024, an estimated $1.45K.
CoreCap Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2021 and held it in 5 quarters.
CoreCap Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $138K in Q2 2022.
11 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2024.

Based on CoreCap Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.